Drug design and enzymatic activity evaluation of coumarin derivatives as potent GSK-3β inhibitors
Drug design and enzymatic activity evaluation of coumarin derivatives
as potent GSK-3β inhibitors
Carla S. Francisco a* (PQ), Heberth de Paula b(PQ), Pedro A. B. Morais b(PQ), Warley de S. Borges a(PQ), Valdemar Lacerda Jr a(PQ)
Federal University of Espírito Santo
a Chemistry Department, Center of Exact Sciences, Campus Goiabeiras, Vitória, ES, Brazil
b Chemistry and Physics Department, CCENS, Campus Alegre, ES, Brazil
*[email protected]
Introduction. Glycogen synthase kinase-3 (GSK-3) is relationed as many protein kinases with phosphorylation and inactivation of glycogen synthase and this finding allowed to this protein the deserved attention of researches, as well as pharmaceutical companies, who were looking for therapeutic targets for Alzheimer’s disease(1, 2). Aim. Considering GSK-3 is seriously intended as a therapeutic target and the development of many additional GSK-3 inhibitors, here in this work is described docking studies and enzymatic activity evaluation against GSK-3β with 10 coumarin derivatives. Methods. Molecular Docking. Docking study was performed using the program Gold Suite 5.1 (CCDC Software Limited), from crystallographic structure of GSK-3β (PDB code: 1Q3D). Docking simulations were performed inside a sphere of 5 Å radius centered at the ligand in the chain A of GSK-3β, considering water molecules W504 and W589, and using the pattern parameters available, a population of 100 conformers, 100.000 operations, 95 mutations and 95 crossovers. The docked lowest-energy structure has a root mean square deviation (RMSD) of 0.576 Å with respect to the corresponding crystal structure of the complex. Enzymatic Activity. GSK-3β activity was measured via a ADP-Glo™ Kinase Commercial Assay that quantifies the kinase-dependent enzymatic production of ADP from ATP using a coupled luminescence-based reaction. The control tube was assumed as 100% enzymatic activity. All reagents were purchased from Promega, LLC. Results. 10 inhibitors candidates were tested at 100M concentration. 2 compounds inhibited more than 50% of the GSK-3β enzymatic activity: 4B (55.38%) and 4A (50.99%). The level of enzymatic inhibition of the other compounds was: 1A (49.62%), 3A (47.34%), 1C (42.33%), 1B (42.10%), 1D (38.97%), 2B (38.51%), 2A (37.48%) and 1E (33.97%). As described by Bertrand et al., Staurosporine, a potent inhibitor of GSK-3β with a reported IC50 value of 15 nM, binds in the ATP-binding site through hydrogen bonds from water-mediated interaction through W504 and W589 molecules. Alsterpaullone (9-nitropaullone), other potent inhibitor, IC50 4 nM, also makes polar interaction with the side-chain amino group of Lys85 in the ATP-binding site. Docking studies performed with the most potent coumarin of the serie 4B and 4A showed that compounds are involved in hydrogen bond interactions with amino group in Lys85 amino acid (2.6 Å) and water-mediated interaction through W589 (3.4 Å) clarifying through the biding mode prediction the important activity in enzymatic assay. Conclusion. Coumarin derivatives 4B and 4A assayed in this work showed remarkable activity as GSK-3β inhibitors as well as interesting binding mode predicted by docking study. References. 1. Beurel E, Grieco SF, Jope RS. Pharmacology & Therapeutics. 2015;148:114-31. 2. Bertrand J, et al. Journal of Molecular Biology. 2003;333(2):393-407. Keywords. Molecular docking, GSK-3β activity, Biochemistry, Medicinal Chemistry, Drug Discovery. Acknowledgments. This work was supported by UFES, FAPES, CAPES and CNPq.